Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Amryt Pharma Plc LSE:AMYT London Ordinary Share GB00BKLTQ412 ORD 6P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 203.50 200.00 207.00 203.50 203.50 203.50 282,630 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 49.2 -56.5 -72.8 - 365

Amryt Pharma Share Discussion Threads

Showing 4851 to 4870 of 6575 messages
Chat Pages: Latest  203  202  201  200  199  198  197  196  195  194  193  192  Older
DateSubjectAuthorDiscuss
27/8/2019
13:04
We are back
alphabravo321
25/8/2019
08:44
Recent abstract on efficacy of Lojuxta/Juxtapid Conclusions Treatment with lomitapide in homozygous familial hypercholesterolaemia patients has a beneficial effect with a constant decrease of low-density lipoprotein cholesterol by 57% compared with classical lipid-lowering therapy and by 54% compared with classical lipid-lowering therapy and time-averaged level of low-density lipoprotein cholesterol. Https://journals.sagepub.com/doi/full/10.1177/2047487319870007?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed
bermudashorts
25/8/2019
08:21
https://epidermolysisbullosanews.com/2019/08/16/amryt-oleogel-s10-phase-3-trial-design-epidermolysis-bullosa/
alphabravo321
23/8/2019
20:40
Could someone give me a nudge please when we’re up and running again. I think I may kick myself for substantially reducing, hey ho!!
bazworth
23/8/2019
20:06
Many thanks alphabravo. Good spot. Excellent news. Aegerion Creditors Approve Drugmaker’s Chapter 11 Plan Bankrupt pharmaceutical company’s chapter 11 plan hands control of assets to Amryt Pharma By Patrick Fitzgerald Aug. 23, 2019 11:43 am ET Creditors of Aegerion Pharmaceuticals Inc. have approved a bankruptcy plan that hands the cholesterol drugmaker’s business to Dublin-based Amryt Pharma PLC. Creditors voted overwhelmingly to support the drugmaker’s chapter 11 plan >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> Hopefully we'll see the admissions document soon.
papillon
23/8/2019
18:05
Excellent and thanks for posting it. Hopefully we'll hear more next week.
waterloo01
23/8/2019
17:45
https://www.wsj.com/articles/aegerion-creditors-approve-drugmakers-chapter-11-plan-11566575038
alphabravo321
23/8/2019
12:51
The timeline in the initial announcement did have a health warning advising it was indicative only...The former CEO is objecting to being treated as a creditor as he has legal indemnity from Aegerion, as in they pay his legal bills and they are treating this as a debt owed rather than an obligation
alphabravo321
23/8/2019
12:40
hTTps://www.law360.com/bankruptcy/articles/1191638/aegerion-pharma-s-ex-ceo-objects-to-ch-11-plan What does it say, alphabravo? Only you have to register to read the article. I'm beginning to doubt that this Aegerion acquisition will happen. The admissions doc was promised for early August and no sign of it. Also no updates from AMYT. Time will tell.
papillon
23/8/2019
12:35
The link doesn't load, alphabravo.
papillon
23/8/2019
12:20
https://www.law360.com/bankruptcy/articles/1191638/aegerion-pharma-s-ex-ceo-objects-to-ch-11-plan?nl_pk=c1b611ce-45ab-489e-a7e4-cc86bdbee3a4&utm_source=newsletter&utm_medium=email&utm_campaign=bankruptcy
alphabravo321
22/8/2019
17:50
Https://tinyurl.com/Amryt-Pharma Amryt Pharma: The AIM drug developer potentially sitting on a US$100mln piece of paper Amryt has a chance of being awarded a priority review voucher, which sell for several times more than the company’s current market cap
delta0091
22/8/2019
13:14
alphabravo321 5 Aug '19 - 16:48 - 4699 of 4712 0 0 0 Readmission doc due to be published in early Aug, readmission to trading planned for “early Q4” >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> Where's this admissions doc, alphabravo? It's late August now and no sign of that bloody admissions doc. I can see the relisting date slipping into 2020.
papillon
22/8/2019
13:12
They do indeed, waterloo01.
papillon
22/8/2019
09:18
See Astra zenica bought a priority review voucher for $95m (down from some years ago). Don't AMYT have one of these if ap101 gets approval?
waterloo01
20/8/2019
19:16
hxxps://risemedia.net/2019/08/07/acromegaly-drug-market-top-competitors-are-silence-therapeutic-strongbridge-biopharma-plc-amryt-pharma-plc-foresee-pharmaceuticals-co-ltd-ipsen-pharma-and-others/ Acromegaly Drug Market Top Competitors are Silence Therapeutic, Strongbridge Biopharma plc, Amryt Pharma plc, Foresee Pharmaceuticals Co., Ltd, Ipsen Pharma and Others Acromegaly is a rare hormonal disorder also known as gigantism. It occurs when pituitary gland releases excessive growth hormone in the body due to the tumor formation in the pituitary gland. This abnormal production of growth hormone results in the bone enlargement. It mainly affects the geriatric population. Global Acromegaly Drug Market is rising gradually with a substantial CAGR of 5.10% in the forecast period of 2019-2026. This rise in market value can be attributed in increase in awareness and concerns regarding the health of patients, increasing prevalence of growth hormone disorders and high expenditure in healthcare sector.
delta0091
19/8/2019
13:09
Well no new update from AMYT since the result of the AGM RNS dated 10th July. Will this drag into 2020 before AMYT relists? From my previous experience of AIM listed companies (including AMYT) they almost always never stick to the initial timetables.
papillon
12/8/2019
15:49
Yes Bermuda I heard of Amryt through Debra Ireland a few years ago. An excellent charity.
chica1
10/8/2019
18:03
DEBRA of America is a high profile Epidermolysis Bullosa medical research charity and they will be hosting their annual benefit evening in New York in October. Amryt is one of three companies (& the only non US one) being recognised with a Partners in Progress award to be presented on the night. Good stuff and well done Amryt. Https://debra.salsalabs.org/2019benefit/index.html
bermudashorts
10/8/2019
10:42
Hi Chica1....As per Newton’s Third Law - Every action has an equal and opposite reaction. Put simply, I have been on this site long enough to realise that Papillon is usually reacting to others comments, rather than irritating others as his primary objective. As for yourself, all the best with the medical condition which afflicts your family. EB is a nasty disease. Previous trials with episalvan have shown a 10% improvement in the skin healing; I would doubt that you would be able to notice significant improvement in a single participant study!
diamondstar1
Chat Pages: Latest  203  202  201  200  199  198  197  196  195  194  193  192  Older
ADVFN Advertorial
Your Recent History
LSE
AMYT
Amryt Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210417 09:46:57